Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | ST6GAL1 | P15907 | 3/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12702728 | 0.85 | DCK (0.39) | LMNAPOLBALB | |
| SCHEMBL16131588 | 0.85 | ST6GAL1 (0.40) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL12702742 | 0.78 | NT5E (0.42) | LMNASLC29A1MAPT | |
| SCHEMBL7165495 | 0.77 | ST6GAL1 (0.37) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL7166943 | 0.76 | NT5E (0.38) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10017438 | 0.76 | PDE3A (0.56) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL12702721 | 0.76 | TSHR (0.32) | LMNAPOLBMAPT | |
| SCHEMBL7158886 | 0.76 | ST6GAL1 (0.40) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL7157425 | 0.76 | NT5E (0.40) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL12702778 | 0.75 | LMNA (0.45) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846636-B2 | Nucleoside analogues with quaternary carbon stereogenic centers and methods of use | LCB PHARMA INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | NUDT1, NT5C3B, NTPCR | LMNA 1770/4885THRB 4121/4885MTOR 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.